The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study

Mon, 02nd Nov 2020 20:03

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Sensyne Health PLC - clinical artificial intelligence company - Notes its CVm-Health+a software application is being used to facilitate the rapid Covid-19 antigen testing study by the University of Oxford. The FACTS study is one of the three university pilot projects established by the UK Department for Health & Social Care and Public Health England. Sensyne's app will be used to provide access to study information and links to training materials and will record health status and test result data for students and staff.

----------

Lamprell PLC - United Arab Emirates based oil rig construction business - Wins "medium-sized" contract from International Maritime Industries to undertake engineering design services. IMI is a joint venture between Saudi Aramco, Lamprell, Bahri and Hyundai Heavy Industries. Lamprell defines a "medium-sized contract" as between USD6 million and USD50 million. The work will start immediately and is expected to take three years, with an initial phase incorporating full detailed design engineering, followed by the production design phase.

----------

Restore PLC - AIM-listed support services company - Acquires E Recycling Ltd, a high security IT asset destruction business for an undisclosed fee. "Euro Recycling is a profitable business and is expected to generate revenues of approximately GBP2.5 million per annum. By bringing Euro Recycling into the group's market leading ITAD platform, the board sees significant opportunity to accelerate growth," Restore said.

----------

San Leon Energy PLC - independent oil and gas exploration company - Notes further three-week extension over its proposed investment in Decklar Petroleum Ltd and the Oza field in Nigeria. The extension has been moved to November 21. The extension is to finalise certain conditions precedent in the subscription agreement, which have taken longer to conclude due to travel restrictions in place as a response to Covid-19, San Leon said.

----------

Synairgen PLC - Southampton University spin-off working in drug discovery and biotechnology - Raises GBP7 million through open offer, giving the firm total proceeds of GBP87 million from its recent placing. Will admit 34.8 million new shares, with 30.8 million from its placing and 4.0 million via the open offer.

----------

Gresham House PLC - UK-based specialist alternative asset manager - Sells 50 megawatt battery storage project to London-listed Gresham House Energy Storage Fund PLC. The project located near Thurcroft, to the east of Rotherham was sold for a total enterprise value of approximately GBP32.5 million, plus up to GBP750,000 of deferred contingent consideration. The investment in the project is consistent with exceeding Gresham House's 15% return on balance sheet capital threshold over the medium term. After this sale, Gresham House has an exposure of GBP3.6 million in the remaining battery storage development projects it has funded, which are in exclusivity with Gresham House Energy Storage Fund.

----------

Creo Medical Group PLC - medical device company - Receives 510(k) clearance from the US Food & Drug Administration for its tissue ablation device MicroBlate Fine. Creo notes the is the third device to gain FDA regulatory clearance within Creo's portfolio of flexible endoscopy devices for the gastrointestinal market. MicroBlate tissue ablation technology utilises Creo's very high frequency microwave energy allowing physicians to precisely ablate diseased tissue in multiple organ types and many different clinical access methods, Creo says. "With regulatory clearance in the UK and Europe and US clearances coming through, we are gearing up for first clinical use of these products in various markets. This rapid progression of device clearances, along with the recent dramatic expansion of Creo's Global commercial sales capability, puts Creo in great shape to drive global commercialisation," Chief Executive Craig Gulliford added.

----------

Kromek Group PLC - supplier of radiation detection components and devices - Enters into a development agreement, worth up to USD660,000, with an unnamed US-based industrial OEM with a global customer base, according to Kromek. The majority of the development programme is scheduled to be delivered during the Kromek's current financial year and, following final completion, it is expected to transition to a multi-year supply contract. For the deal, Kromek will customise one of its CZT detector platforms for incorporation into the customer's systems for identifying contaminations during production processes.

----------

Sabien Technology Group PLC - AIM-listed energy efficiency technology firm - Confirms negotiations are still ongoing with Ptarmigan Health Destinations SA over a potential acquisition deal. Says further details will be announced in due course.

----------

Mode Global Holdings PLC - banking, payments, investment, and loyalty programme digitalisation firm - Completes the buy-out of the 45% minority interest in its payments operating subsidiary - JGOO Ltd, which operates as part of Mode for Business - from Pure NZ Gateway Ltd. The transaction price was not disclosed. The transaction includes the purchase of JGOO's technology and the rights associated to it. "Buying out Pure NZ Gateway consolidates Mode's business and value proposition," Mode said.

----------

Watchstone Group PLC - insurance, technology and healthcare firm - Completes sale of Ingenie business. As a result, is now a cash shell and has until May 1 to complete an acquisition or reverse takeover. Alternatively, can re-admit shares to AIM as an investment company, but will need to raise at least GBP6 million for that to happen.

----------

Curzon Energy PLC - investor in US based natural gas projects - Remains in discussions with Sun Seven Stars Investment Group over a potential extension of the exclusivity period with a view to a transaction, the terms of which have yet to be agreed. "While the parties continue to work constructively towards renewing exclusivity and a potential transaction, there can be no certainty around the length of time required to reach definitive agreement or the likelihood of concluding a successful transaction," Curzon adds.

----------

K3 Business Technology Group PLC - Enterprise software company - Says trading in the second half of the financial year ending November 30 was in line with the second quarter and management expectations. K3 says its own IP and Global Accounts businesses showed "particular resilience". Also noted its second half is typically stronger. "October is an important month for annual software licence and maintenance contract renewals, and these have progressed well with renewal rates tracking at normal high levels," K3 added. Continues to focus on expanding own IP sales, particularly the K3-imagine platform.

----------

Seneca Global Income & Growth PLC - trust hoping to combine the benefits of a quarterly income with long term capital growth - Renews GBP10 million revolving credit facility with The Royal Bank of Scotland International Ltd, London Branch for a further two years. The facility bears interest at 1.05% over LIBOR and may be used for the acquisition of investments in accordance with the company's investment policy and for the funding of share buy backs and dividend payments.

----------

ADES International Holding PLC - drilling oil and gas wells company - Secures a new two-year early production facility contract in Egypt. Under the agreement, ADES will establish an early production deck floor and top side facilities in addition to a jack-up barge charter. Also notes it has successfully extended the contract for Rig 40 in Saudi Arabia for an additional three months to the end of the first quarter of 2021.

----------

Adriatic Metals PLC - precious and base metals explorer and developer - Completes binding subscription agreement with the European Bank for Reconstruction & Development, where the bank to subscribe for 5.3 million shares at GBP1.175 per share. Adriatic closed at 118.00 pence in London on Monday.

----------

Coro Energy PLC - South East Asian energy company focused on transition to a low carbon economy - Acquires 20% shareholding in ion Ventures Holdings Ltd, a South East Asian and UK focused developer of clean energy projects, including renewables and battery storage for cash consideration of GBP500,000. Alongside this initial investment, the company has been granted a priority right of first refusal to invest in each of ion Venture's South East Asian projects prior to financial close. Coro says the deal gives it immediate access to the existing ion Ventures pipeline of approximately 20 high quality clean energy projects.

----------

Ascent Resources PLC - independent oil and gas exploration company with a focus on European onshore projects - Further to the announcements of 14 and 30 April 2020, it has agreed a six month extension to the Memorandum of Understanding which it has signed with Cupet, the Cuban national oil company. The MoU gives Ascent the exclusive right to negotiate the production sharing contracts for the onshore producing Block 9B and onshore exploration Blocks 9A, 12 and 15.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
5 Sep 2022 10:42

Synairgen to collaborate with University of Southampton on observational study

(Sharecast News) - Drug discovery outfit Synairgen will collaborate with the University of Southampton on an observational study aimed at exploring and better understanding acute respiratory viral infections and recovery.

Read more
23 Jun 2022 16:02

UK shareholder meetings calendar - next 7 days

Friday 24 June 
AFC Energy PLCGM re fees for non-executive directors
Avast PLCAGM
Devolver Digital IncAGM
Entain PLCAGM
Gulf Keystone Petroleum LtdAGM
Hawkwing PLCAGM
Invesco Bond Income Plus LtdAGM
Life Science REITAGM
Northcoders Group PLCAGM
Princess Private Equity Holding LtdAGM
Monday 27 June 
Anglo-Eastern Plantations PLCAGM
Celadon Pharmaceuticals PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Echo Energy PLCAGM
Medica Group PLCAGM
Pelatro PLCAGM
Surgical Innovations Group PLCAGM
Warpaint London PLCAGM
Tuesday 28 June 
4D Pharma PLCAGM
Acceler8 Ventures PLCAGM
Airtel Africa PLCAGM
Alina Holdings PLCAGM
Aquila Energy Efficiency Trust PLCAGM
Attraqt Group PLCAGM
Bay Capital PLCAGM
Capital & Counties Properties PLCAGM
CMO Group PLCAGM
Corre Energy BVAGM
Creo Medical Group PLCAGM
Futura Medical PLCAGM
Gama Aviation PLCAGM
ICG Enterprise Trust PLCAGM
ImmuPharma PLCAGM
IQE PLCAGM
Katoro Gold PLCAGM
Rockhopper Exploration PLCAGM
Sound Energy PLCAGM
TP Group PLCAGM
UK Oil & Gas PLCAGM
Volvere PLCAGM
Zegona Communications PLCAGM
Wednesday 29 June 
Africa Opportunity Fund LtdAGM
Argo Blockchain PLCAGM
Atome Energy PLCAGM
Brave Bison Group PLCAGM
Concurrent Technologies PLCAGM
Eden Research PLCAGM
Facilities by ADF PLCAGM
Gemfields Group LtdAGM
Golden Prospect Precious Metals LtdAGM
HeiQ PLCAGM
Helios Underwriting PLCAGM
Hurricane Energy PLCAGM
i(x) Net Zero PLCAGM
Lords Group Trading PLCAGM
MaxCyte IncAGM
Meggitt PLCAGM
Mobile Tornado Group PLCAGM
NB Distressed Debt Investment Fund LtdAGM
NetScientific PLCAGM
Provident Financial PLCAGM
RA International Group PLCAGM
Reabold Resources PLCAGM
Symphony Environmental Technologies PLCAGM
Team17 Group PLCAGM
ThinkSmart LtdGM re approval for capital return
Trinity Exploration & Production PLCAGM
URA Holdings PLCAGM
XP Factory PLCAGM
Zaim Credit Systems PLCAGM
Thursday 30 June 
3i Group PLCAGM
Ashtead Technology Holdings PLCAGM
Borders & Southern Petroleum PLCAGM
Caspian Sunrise PLCAGM
Cobra Resources PLCAGM
Crimson Tide PLCAGM
ECSC Group PLCAGM
Evraz PLCAGM
Gresham House Energy Storage Fund PLCAGM
GRIT Investment Trust PLCAGM
Gulf Marine Services PLCAGM
Hamak Gold LtdAGM
Hemogenyx Pharmaceuticals PLCAGM
Immotion Group PLCAGM
Inspiration Healthcare Group PLCAGM
Inspired PLCAGM
Jadestone Energy PLCAGM
Kanabo Group PLCAGM
Kropz PLCAGM
Likewise Group PLCAGM
Live Co Group PLCAGM
Location Sciences Group PLCAGM
LoopUp Group PLCAGM
M&C Saatchi PLCAGM
Microsaic Systems PLCAGM
Nostra Terra Oil & Gas CoAGM
Pathfinder Minerals PLCAGM
Playtech PLCAGM
Primorus Investments PLCAGM
Rockfire Resources PLCAGM
Roquefort Therapeutics PLCAGM
Sanne Group PLCAGM
Scottish Mortgage Investment Trust PLCAGM
Serica Energy PLCAGM
Supply@ME Capital PLCAGM
Surface Transforms PLCAGM
Synairgen PLCAGM
Tower Resources PLCAGM
Trainline PLCAGM
ValiRx PLCAGM
Victoria Oil & Gas PLCAGM
Watchstone Group PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
25 May 2022 12:00

IN BRIEF: Synairgen shares fall as loss widens on higher costs

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Records a pretax loss of GBP57.9 million in 2021, widened from GBP17.7 million in 2020, as research and development costs jump to GBP52.9 million from GBP15.5 million. Further, administrative expenses more than double to GBP5.0 million from GBP2.2 million. Explains this with its phase 3 Sprinter trial that started patient recruitment in January 2021. The trial is for SNG001, an inhaled drug for the treatment of Covid-19. Says the remainder of the research and development expenditure was used for upscaling SNG001 manufacturing development activities and procuring long lead time components.

Read more
16 May 2022 15:23

Synairgen posts positive clinical trial data for SNG001

(Sharecast News) - Shares of Synairgen caught a bid following the release of clinical trial results which appeared to show that its SNG001 formulation against Covid-19 might lower the risk of severe disease or death in the most at risk patients.

Read more
16 May 2022 12:18

LONDON MARKET MIDDAY: FTSE 100 edges into green but grey clouds remain

(Alliance News) - The FTSE 100 index put a toe into positive territory by midday on Monday, reclaiming all the ground lost earlier in the morning, but investors continue to fret about poor economic data from China.

Read more
16 May 2022 12:18

IN BRIEF: Synairgen shares soar on positive analysis of SNG001

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Notes that it announced in February that its phase 3 Sprinter trial did not meet its primary endpoints of discharge from hospital and recovery. Says that the trial still showed an encouraging signal in the reduction in the relative risk of progression to severe disease or death within 35 days. Says that it performed a post hoc analysis on groups of patients recognised to be at greater risk of developing severe disease in hospital, to assess the strength of this signal. Says that the analyses showed stronger treatment effects with SNG001 in high-risk patient sub-groups, with the strongest effect observed in those who had clinical signs of compromised respiratory function. Says SNG001 significantly reduced the risk of progression to severe disease and death compared to a placebo by 70% in the per-protocol population.

Read more
17 Mar 2022 12:32

Synairgen falls as patient recruitment halted on Covid-19 trial

(Sharecast News) - Inhaled antiviral treatment developer Synairgen said on Thursday that the US National Institute of Allergy and Infectious Diseases (NIAID) has halted all patient recruitment in its phase 2 and 3 Covid-19 trial, which included the assessment of its 'SNG001' treatment.

Read more
17 Mar 2022 11:48

IN BRIEF: Synairgen falls as patient recruitment in US trial halted

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Says the US National Institute of Allergy & Infectious Diseases has halted all patient recruitment in its phase 2/3 Covid-19 trial. The trial included the assessment of its inhaled SNG001 drug.

Read more
17 Mar 2022 11:21

AIM WINNERS & LOSERS: Synairgen sinks 18% after US Covid study halted

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
3 Mar 2022 20:34

TRADING UPDATES: Next Fifteen raises GBP50 million; N Brown sales up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
3 Mar 2022 12:20

Synairgen asked to pause activities on Covid-19 treatment trial

(Sharecast News) - Synairgen announced on Thursday that it was pausing clinical trial activities on its 'SNG001' compound in the treatment of Covid-19, at the behest of American authorities.

Read more
3 Mar 2022 11:29

AIM WINNERS & LOSERS: dotDigital plunges after profit warning

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
21 Feb 2022 12:25

Synairgen falls as trial for Covid treatment fails to meet endpoints

(Alliance News) - Synairgen PLC shares hit a 12-month low on Monday after the biotechnology company said that the late-stage trial of its Covid-19 treatment SNG001 did not meet primary or key secondary efficacy endpoints.

Read more
21 Feb 2022 11:33

AIM WINNERS & LOSERS: Morses Club sinks on profit warning, CEO exit

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
21 Feb 2022 09:27

Synairgen shares plunge as Covid-19 treatment trial fails

(Sharecast News) - Synairgen announced on Monday that the international phase 3 trial of its SNG001 antiviral inhalation in patients hospitalised with Covid-19 did not meet its primary or key secondary endpoints.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.